First Eagle Investment Management LLC Sells 41,215 Shares of Elevance Health, Inc. $ELV

07 Nov 2025, 05:40 by Amy Steele · The Cerbat Gem

First Eagle Investment Management LLC cut its holdings in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 1.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,200,146 shares of the company’s stock after selling 41,215 shares during the quarter. Elevance Health comprises 2.4% of First Eagle Investment Management LLC’s portfolio, making the stock its 13th biggest holding. First Eagle Investment Management LLC owned 1.42% of Elevance Health worth $1,244,729,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. GLOBALT Investments LLC GA raised its position in shares of Elevance Health by 0.4% in the first quarter. GLOBALT Investments LLC GA now owns 6,306 shares of the company’s stock valued at $2,743,000 after purchasing an additional 24 shares during the period. Hemington Wealth Management grew its stake in Elevance Health by 13.3% in the 1st quarter. Hemington Wealth Management now owns 230 shares of the company’s stock valued at $100,000 after buying an additional 27 shares during the last quarter. Aspen Investment Management Inc raised its holdings in Elevance Health by 2.6% in the 1st quarter. Aspen Investment Management Inc now owns 1,048 shares of the company’s stock valued at $456,000 after acquiring an additional 27 shares during the period. Prudent Man Advisors LLC lifted its position in Elevance Health by 2.3% during the first quarter. Prudent Man Advisors LLC now owns 1,257 shares of the company’s stock worth $547,000 after acquiring an additional 28 shares during the last quarter. Finally, Generali Investments Towarzystwo Funduszy Inwestycyjnych boosted its holdings in shares of Elevance Health by 5.3% during the first quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 600 shares of the company’s stock worth $261,000 after acquiring an additional 30 shares during the period. Institutional investors and hedge funds own 89.24% of the company’s stock.

Insider Buying and Selling

In other Elevance Health news, Director Susan D. Devore bought 1,200 shares of the business’s stock in a transaction on Tuesday, August 19th. The stock was purchased at an average cost of $312.15 per share, for a total transaction of $374,580.00. Following the completion of the purchase, the director directly owned 3,502 shares of the company’s stock, valued at approximately $1,093,149.30. This trade represents a 52.13% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 0.29% of the stock is currently owned by corporate insiders.

Elevance Health Stock Down 0.9%

Shares of NYSE ELV opened at $315.08 on Friday. The stock has a market capitalization of $70.02 billion, a P/E ratio of 12.88, a PEG ratio of 1.23 and a beta of 0.60. The stock’s fifty day moving average is $329.44 and its 200 day moving average is $345.97. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $458.75. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.56 and a current ratio of 1.56.

Elevance Health (NYSE:ELV – Get Free Report) last posted its quarterly earnings data on Tuesday, October 21st. The company reported $6.03 earnings per share for the quarter, topping the consensus estimate of $5.03 by $1.00. Elevance Health had a net margin of 2.84% and a return on equity of 16.17%. The business had revenue of $50.09 billion during the quarter, compared to analysts’ expectations of $49.26 billion. During the same quarter in the prior year, the business posted $8.37 earnings per share. Elevance Health’s revenue was up 12.0% compared to the same quarter last year. Sell-side analysts forecast that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 19th. Investors of record on Friday, December 5th will be paid a $1.71 dividend. This represents a $6.84 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Friday, December 5th. Elevance Health’s dividend payout ratio (DPR) is 27.96%.

Analysts Set New Price Targets

ELV has been the topic of a number of recent research reports. Mizuho lowered their target price on Elevance Health from $420.00 to $400.00 and set an “outperform” rating on the stock in a research note on Monday. Wells Fargo & Company decreased their price objective on Elevance Health from $412.00 to $403.00 and set an “overweight” rating on the stock in a report on Wednesday, October 22nd. Argus reiterated a “hold” rating on shares of Elevance Health in a research report on Monday, July 21st. Truist Financial set a $400.00 target price on Elevance Health in a report on Tuesday, October 14th. Finally, Weiss Ratings upgraded shares of Elevance Health from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, October 8th. Twelve investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Elevance Health currently has an average rating of “Moderate Buy” and an average target price of $397.33.

Get Our Latest Stock Analysis on ELV

Elevance Health Profile

(Free Report)

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.